Biogen announce they have stopped SCA3 clinical trial

Ataxia UK were saddened to hear that Biogen have stopped their Phase I clinical trial for SCA3 therapeutic BIIB132 (MERA study). The trial was planned to be an international study, including a small number of people with SCA3 in the UK (read the original study announcement here). 

The decision to stop the trial was made after careful assessment of the nonclinical safety data, clinical pharmacodynamic data, and future development of BIIB132. 

Read the letter from Biogen Medical Director, Dr Rosalind Chuang here.